Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hutchmed China Ltd ADR
(NQ:
HCM
)
17.45
-0.31 (-1.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Hutchmed China Ltd ADR
< Previous
1
2
3
4
5
6
Next >
Hutchmed scores U.S. success with cancer drug, but profits still dip
August 15, 2024
Key Takeaways: Hutchmed’s U.S. sales jumped nearly 53% in the second quarter from the previous three months, boosted by uptake of the cancer drug Fruzaqla The company plans to focus on innovative drugs...
Via
Benzinga
Why HUTCHMED Stock Is Moving Higher Friday
July 05, 2024
HUTCHMED announced that its New Drug Application for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status.
Via
Benzinga
Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
May 09, 2024
Via
Benzinga
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 14, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 13, 2024
Via
Benzinga
Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
March 13, 2024
Shares of SurgePays, Inc. (NASDAQ: SURG) fell sharply in today’s pre-market trading after the company reported worse-than-expected fourth-quarter financial results.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 13, 2024
Pre-market stock movers are a great way to start the day with all of the hottest news worth reading about on Wednesday morning!
Via
InvestorPlace
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
March 13, 2024
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday.
Via
Benzinga
Airbnb Reports Q4 Results, Joins MGM Resorts, Upstart And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
February 14, 2024
U.S. stock futures were higher this morning, with the Nasdaq futures trading higher by around 80 points on Wednesday.
Via
Benzinga
Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets
February 03, 2024
Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones.
Via
Talk Markets
Broadcom To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday
November 24, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Goldman Sachs Maintains Neutral Rating for HUTCHMED (China): Here's What You Need To Know
November 10, 2023
Via
Benzinga
CRISPR Therapeutics Stock Earns IBD Stock Rating Upgrade
November 08, 2023
On Wednesday, CRISPR Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85, up from 68 a day earlier.
Via
Investor's Business Daily
Rocket Pharmaceuticals Stock Sees Improved Price Strength
November 02, 2023
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78
Via
Investor's Business Daily
Apellis Pharmaceuticals Stock Improves With An RS Ratings Over 90
October 31, 2023
Apellis Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
October 30, 2023
Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.
Via
Benzinga
Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher
October 27, 2023
A Relative Strength Rating upgrade for Rocket Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday
October 27, 2023
U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
October 24, 2023
A Relative Strength Rating upgrade for Apellis Pharmaceuticals shows improving technical performance. Will it continue?
Via
Investor's Business Daily
Revolution Medicines Stock Joins Elite Club With RS Ratings Over 90
October 16, 2023
Revolution Medicines shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
AZZ, VOXX International And Other Big Stocks Moving Higher On Wednesday
October 11, 2023
U.S. stocks traded higher Wednesday, with the Dow Jones gaining around 100 points. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Sarepta Therapeutics Stock Showing Rising Relative Strength
October 09, 2023
Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
September 28, 2023
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.
Via
Investor's Business Daily
Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating
September 27, 2023
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.
Via
Investor's Business Daily
Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
September 11, 2023
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca
August 26, 2023
China’s drug distributors are in the hunt to acquire Poland’s Neuca, a company with a 32% market share of Poland’s pharmaceutical distribution business. The consortium of China’s drug distributors may...
Via
Talk Markets
Hutchmed's Candidate Achieves Main Goal In China's Rare Blood Disorder Study
August 21, 2023
HUTCHMED (China) Limited's (NASDAQ: HCM) pivotal Phase 3 trial ESLIM-01 evaluating the investigational use of sovleplenib met its primary endpoint of durable response rate and all secondary endpoints...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.